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Ajoke.sobanjo-termeulen@gatesfoundation.orgOverwhelming evidence demonstrates the beneﬁts of vaccines
o individuals (both children and adults) and to the public, pri-
arily via herd immunity. The Global Vaccine Action Plan (GVAP),
pproved by the World Health Assembly in 2012, strives to ‘pro-
ide full beneﬁts of vaccination to all people’, while Millennium
evelopment Goals 4 and 5 work toward reduced child mortality
nd improved maternal health. Immunizing mothers during preg-
ancy (MI) against vaccine-preventable diseases has the potential
o improve health outcomes in both mothers and their infants and
o meet GVAP and Millennium Goals. MI  may  emerge as a key strat-
gy to address neonatal mortality in particular, which accounts for
lmost half of all under ﬁve deaths globally.
Aside from the success of the Maternal and Neonatal Tetanus
limination (MNTE) program, population data are now available for
ther successful MI  programs, for example, in Argentina (described
n this issue), and in the United Kingdom [1]. These programs have
emonstrated the feasibility and effectiveness of MI  programs in
igh, medium and low income counties. No safety signals related to
he vaccines administered as part of these programs were observed.
An increasing amount of data regarding the efﬁcacy and
mmunogenicity of MI  in both mothers and their infants are becom-
ng available. For example, studies have demonstrated the efﬁcacy
f inﬂuenza vaccines in protecting pregnant women  and their
nfants, and the safety and effectiveness of maternal Tdap vacci-
ation has been demonstrated in a large population of pregnant
omen [1–3]. There is the potential for the results of ongoing trials
f new RSV and GBS vaccines to contribute to the basis of licensure
or a MI  indication. An enabling regulatory and policy environment
ould facilitate introduction of new, and expanding indications of
icensed, vaccines to include pregnant women.
However, major knowledge gaps and implementation chal-
enges remain. They are related to the lack of descriptive
pidemiologic data, especially in low and medium income
ountries (LMICs); the lack of harmonized deﬁnitions across
tudies, allowing meta-analyses and improved pharmacovigilance
cross studies and reporting systems; better understanding of
nfrastructure and experience with conducting clinical trials in
MICs settings; lack of integrated approaches to antenatal care, etc.
he manuscripts included in this issue attempt to address some
f these challenges: several studies describe the epidemiology of
accine-preventable diseases (Polack et al., Halasa et al., Searle
t al.); address harmonization of terms and deﬁnitions (Munoz
t al.; Fulton et al.); provide perspective by researchers in LICs
Laufer et al., Cutland et al.); and describe regulatory (Gruber) and
thical (White and Madhi) aspects of MI.
Strong partnerships among a diverse set of institutions and
eographies are needed to overcome knowledge gaps, implement
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.085
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article ustudies, develop polices, and evaluate the efﬁcacy and effective-
ness of MI.  A conference organized by NIH and BMGF in 2014 was
a collaborative effort that brought together key global experts and
stakeholders. Some authors of the manuscripts in this issue were
presenters at the conference. The objectives of the conference and
this special issue of Vaccine are to address knowledge gaps and
identify approaches to move this important ﬁeld forward world-
wide.
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